Works matching IS 01676997 AND DT 2020 AND VI 38 AND IP 2

Results: 32
    1
    2
    3
    4
    5

    Anticancer activities of vitamin K3 analogues.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 378, doi. 10.1007/s10637-019-00855-8
    By:
    • Wellington, Kevin W.;
    • Hlatshwayo, Vincent;
    • Kolesnikova, Natasha I.;
    • Saha, Sourav Taru;
    • Kaur, Mandeep;
    • Motadi, Lesetja R.
    Publication type:
    Article
    6

    Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 485, doi. 10.1007/s10637-019-00836-x
    By:
    • Yoshiya, Tomoharu;
    • Mimae, Takahiro;
    • Ito, Masaoki;
    • Sasada, Shinsuke;
    • Tsutani, Yasuhiro;
    • Satoh, Kenichi;
    • Masuda, Takeshi;
    • Miyata, Yoshihiro;
    • Hattori, Noboru;
    • Okada, Morihito
    Publication type:
    Article
    7
    8

    Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 533, doi. 10.1007/s10637-019-00822-3
    By:
    • Ishikawa, Masashi;
    • Iwasa, Satoru;
    • Nagashima, Kengo;
    • Aoki, Masahiko;
    • Imazeki, Hiroshi;
    • Hirano, Hidekazu;
    • Shoji, Hirokazu;
    • Honma, Yoshitaka;
    • Okita, Natsuko;
    • Takashima, Atsuo;
    • Kato, Ken;
    • Saruta, Masayuki;
    • Boku, Narikazu
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 468, doi. 10.1007/s10637-019-00787-3
    By:
    • Ebata, Takahiro;
    • Shimizu, Toshio;
    • Fujiwara, Yutaka;
    • Tamura, Kenji;
    • Kondo, Shunsuke;
    • Iwasa, Satoru;
    • Yonemori, Kan;
    • Shimomura, Akihiko;
    • Kitano, Shigehisa;
    • Koyama, Takafumi;
    • Sato, Natsuko;
    • Nakai, Kiyohiko;
    • Inatani, Michiyasu;
    • Yamamoto, Noboru
    Publication type:
    Article
    20

    A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 457, doi. 10.1007/s10637-019-00783-7
    By:
    • van Brummelen, Emilie M. J.;
    • Levchenko, Evgeny;
    • Dómine, Manuel;
    • Fennell, Dean A.;
    • Kindler, Hedy L.;
    • Viteri, Santiago;
    • Gadgeel, Shirish;
    • López, Pilar Garrido;
    • Kostorov, Vladimir;
    • Morgensztern, Daniel;
    • Orlov, Sergey;
    • Zauderer, Marjorie G.;
    • Vansteenkiste, Johan F.;
    • Baker-Neblett, Katherine;
    • Vasquez, James;
    • Wang, Xiaowei;
    • Bellovin, David I.;
    • Schellens, Jan H. M.;
    • Yan, Li;
    • Mitrica, Ionel
    Publication type:
    Article
    21

    Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 340, doi. 10.1007/s10637-019-00786-4
    By:
    • Jeon, Jae Yoon;
    • Zhao, Qiuhong;
    • Buelow, Daelynn R.;
    • Phelps, Mitch;
    • Walker, Alison R.;
    • Mims, Alice S.;
    • Vasu, Sumithira;
    • Behbehani, Gregory;
    • Blachly, James;
    • Blum, William;
    • Klisovic, Rebecca B.;
    • Byrd, John C.;
    • Garzon, Ramiro;
    • Baker, Sharyn D.;
    • Bhatnagar, Bhavana
    Publication type:
    Article
    22
    23
    24
    25

    A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 445, doi. 10.1007/s10637-019-00780-w
    By:
    • Yamamoto, Noboru;
    • Ryoo, Baek-Yeol;
    • Keam, Bhumsuk;
    • Kudo, Masatoshi;
    • Lin, Chia-Chi;
    • Kunieda, Futoshi;
    • Ball, Howard A.;
    • Moran, Diarmuid;
    • Komatsu, Kanji;
    • Takeda, Kentaro;
    • Fukuda, Musashi;
    • Furuse, Junji;
    • Morita, Satoshi;
    • Doi, Toshihiko
    Publication type:
    Article
    26
    27
    28
    29

    Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 419, doi. 10.1007/s10637-019-00776-6
    By:
    • Shapiro, Geoffrey I.;
    • LoRusso, Patricia;
    • Kwak, Eunice;
    • Pandya, Susan;
    • Rudin, Charles M.;
    • Kurkjian, Carla;
    • Cleary, James M.;
    • Pilat, Mary Jo;
    • Jones, Suzanne;
    • de Crespigny, Alex;
    • Fredrickson, Jill;
    • Musib, Luna;
    • Yan, Yibing;
    • Wongchenko, Matthew;
    • Hsieh, Hsin-Ju;
    • Gates, Mary R.;
    • Chan, Iris T.;
    • Bendell, Johanna
    Publication type:
    Article
    30

    Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 2, p. 433, doi. 10.1007/s10637-019-00771-x
    By:
    • Fan, Bin;
    • Mellinghoff, Ingo K.;
    • Wen, Patrick Y.;
    • Lowery, Maeve A.;
    • Goyal, Lipika;
    • Tap, William D.;
    • Pandya, Shuchi S.;
    • Manyak, Erika;
    • Jiang, Liewen;
    • Liu, Guowen;
    • Nimkar, Tara;
    • Gliser, Camelia;
    • Prahl Judge, Molly;
    • Agresta, Sam;
    • Yang, Hua;
    • Dai, David
    Publication type:
    Article
    31
    32